Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.96 |
| ▸ | DRD3 known ✓ | P35462 | 7/20 | 0.96 |
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.96 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.68 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.68 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.61 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.61 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.51 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.51 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.51 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.51 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.51 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.51 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.51 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.51 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2217039 | 1.00 | DRD2 (0.96) | DRD2DRD3ADRB1HTR1ACYP1A2 | |
| Hydrochloric Acid SCHEMBL246338 | 1.00 | DRD2 (0.96) | DRD2DRD3ADRB1HTR1ACYP1A2 | |
| Piperazine SCHEMBL28169968 | 0.98 | DRD2 (0.93) | DRD2DRD3ADRB1HTR1ACYP1A2 | |
| SCHEMBL8511 | 0.98 | DRD2 (1.00) | DRD2DRD3ADRB1HTR1ACYP1A2 | |
| SCHEMBL6352699 | 0.98 | DRD2 (1.00) | DRD2DRD3ADRB1HTR1ACYP1A2 | |
| SCHEMBL29367982 | 0.98 | DRD2 (1.00) | DRD2DRD3ADRB1HTR1ACYP1A2 | |
| Bromide SCHEMBL981906 | 0.96 | DRD2 (0.96) | DRD2DRD3ADRB1HTR1ACYP1A2 | |
| Piperazine SCHEMBL28251276 | 0.96 | DRD2 (0.96) | DRD2DRD3ADRB1HTR1ACYP1A2 | |
| Hydrochloric Acid SCHEMBL253371 | 0.93 | DRD2 (0.84) | DRD2DRD3ADRB1HTR1ACYP1A2 | |
| SCHEMBL3609605 | 0.91 | DRD2 (0.87) | DRD2DRD3ADRB1HTR1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874636-A | Preparation method of kalirazine | 鲁南制药集团股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-116178307-B | Synthesis method of 1- (2, 3-dichlorophenyl) piperazine hydrochloride | 浙江大洋生物科技集团股份有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-118026945-A | Synthetic method of brimesalamine | 武汉工程大学 | 2024-05-14 | — | — | CN | claimed |
| CN-117886778-A | Preparation and refining method of 2, 3-dichlorophenyl piperazine hydrochloride | 上海中西三维药业有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-114262283-B | Method for preparing kali lazine and intermediate thereof | 苏州旺山旺水生物医药有限公司 | 2024-03-12 | — | — | CN | claimed |
| CN-117288847-A | Method for measuring content of related substances and preservative of aripiprazole oral solution | 万特制药(海南)有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-116199644-A | Method for preparing 1- (2, 3-dichlorophenyl) piperazine hydrochloride | 浙江华海药业股份有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-116178307-A | Synthesis method of 1- (2, 3-dichlorophenyl) piperazine hydrochloride | 浙江大洋生物科技集团股份有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-115368317-A | Improved method for preparing aripiprazole intermediate | 浙江华海药业股份有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-115340494-A | Synthesis method of high-purity aripiprazole | 安徽修一制药有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-108069900-B | Preparation method and application of aripiprazole hydrochloride | 齐鲁制药有限公司 | 2022-09-23 | — | — | CN | claimed |
| CN-110850012-B | Detection method of 1- (2, 3-dichlorophenyl) piperazine hydrochloride and related substances thereof | 四川弘远药业有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114262283-A | Method for preparing cariprazine and intermediate thereof | 苏州旺山旺水生物医药有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-109251172-B | Synthesis method of aripiprazole | 暨明医药科技（苏州）有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-121800721-A | Aripiprazole Process for preparing azoles | 浙江工业大学 | 2026-04-07 | — | — | CN | disclosed |
| CN-121758364-A | Method for catalytic synthesis of aripiprazole by utilizing hydrogen transfer strategy | 浙江工业大学 | 2026-03-31 | — | — | CN | disclosed |
| CN-116199644-B | Method for preparing 1- (2, 3-dichlorophenyl) piperazine hydrochloride | 浙江华海药业股份有限公司 | 2026-01-09 | — | — | CN | disclosed |
| CN-114262283-A | Method for preparing cariprazine and intermediate thereof | 苏州旺山旺水生物医药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-108484496-B | Aripiprazole hapten and application thereof in immunoassay | 詹森药业有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114213362-A | Preparation method of cariprazine and intermediate compound | 成都栩哲医药科技有限公司 | 2022-03-22 | — | — | CN | disclosed |